The HPV vaccines - Which to prefer?

Obstetrical and Gynecological Survey

Volumn 64, Issue 5, 2009, Pages 345-350

  Bornstein, Jacob ^a  

^a WESTERN GALILEE HOSPITAL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

AUSTRALIA; CANCER GRADING; CANCER IMMUNIZATION; CONDYLOMA ACUMINATUM; DRUG APPROVAL; DRUG EFFICACY; DRUG PREFERENCE; ECUADOR; FOOD AND DRUG ADMINISTRATION; GYNECOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; NONHUMAN; PHILIPPINES; PRECANCER; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CANCER; VIRUS STRAIN; WART VIRUS; ADOLESCENT; ADULT; AGE; ALPHAPAPILLOMAVIRUS; CHILD; FEMALE; IMMUNOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; UTERINE CERVIX TUMOR;

ADOLESCENT; AGE FACTORS; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 67449095322     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e31819f992e     Document Type: Review

References (34)

1. Immunogenicity of GSK Bio's HPV Vaccine versus Merck's Gardasil in healthy females 18-45 years of age. Vaccine. In press. Available at: http://Clinicaltrials.gov/ct2/show/NCT00423046.
2. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-278.
3. 3. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364:1757-1765. (Pubitemid 39488060)
4. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 45 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:1247-1255.
5. Garland SM, Hernandez-Avila M, Wheeler CM, et al; for the FUTURE I investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital disease. N Engl J Med 2007;356:1928-1943.
6. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med 2007;356:1915-1927.
7. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, 18) L1 like particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet 2007;369:1693-1702.
8. Ault KA; FUTURE II Study group. Effect of prophylactic human papillomavirus L1 virus -like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007;369:1861-1868.
9. 9. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus like particle vaccine against infection with HPV 16 and 18 in young women: an interim analysis of a phase III double blind, randomized controlled trial. Lancet 2007;369:2161-2170. (Pubitemid 46977438)
10. Harper D, Gall S, Naud P, et al. Sustained immunogenicity and high efficacy against HPV 16/18 related 6.4 years in women vaccinated with cervarix. Gynecol Oncol 2008;109:158-159.
11. Ferlay F, Bray F, Pisani P, et al. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. Lyon, France: IARC Press; 2005. IARC. CancerBase No.5 Version 2.0.
12. Bosch FX, de SanJose S, Castelsague X. Evaluating the potential benefits of universal worldwide human papillomavirus vaccination. Therapy 2008;5:305-312.
13. Bosch FX, ed. HPV vaccines and screening in the prevention of cervical cancer. Vaccine 2006;24:S1-S262.
14. 14. Bornstein J. Human papillomavirus vaccine: the beginning of the end for cervical cancer. Isr Med Assoc J 2007;9:156-158. (Pubitemid 46470395)
15. 15. Baldridge IR, McGowan P, Evans JT, et al. Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;4:1129-1138. (Pubitemid 38937554)
16. 16. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminum salt combination (ASO4) compared to aluminum salt only. Vaccine 2006;24:5937-5949. (Pubitemid 44080367)
17. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008;110:S1-S10.
18. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 viruslike particle (VLP) vaccine. Vaccine 2007;25:4931-4939.
19. Harper MD. Impact of vaccination with Cervarix on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol 2008;110:S11-S17.
20. Offit PA, Jew RK. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 2003;112:1394-1397.
21. Bosch FX, Castelsague X, de San Jose S. HPV and cervical cancer: screening or vaccination? Br J Cancer 2008;98:15-21.
22. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008;109:S15-S21.
23. Poncelet S, Cambron P, Giannini S, et al. Induction of cervical mucosal HPV IgG in women 15-55 years old following systemic vaccination with Cervarix, the HPV 16/18 AS04 vaccine candidate. Paper presented at: IPC; November 2007; Beijing, China. Abstract.
24. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008;110:S18-S25.
25. Brown D; for the FUTURE study group. HPV type 6/11/ 16/18 vaccine: first analysis of cross protection against persistent infection, CIN and AIS caused by oncogenic HPV types in addition to 16/18. In: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sep 2007; Chicago, IL.
26. 26. de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human apillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-459. (Pubitemid 46962343)
27. Skinner SR, Garland SM, Stanley MA, et al. Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26? Med J Aust 2008;188:238-242.
28. Luna J; Future III study group. Safety, efficacy, immunogenicity of quadrivalent HPV vaccine (Gardasil) in women aged 24-45. In: 24th International Papillomavirus Congress; November 3-9, 2007; Beijing, China.
29. Schwartz T, Descamps D. Immune Response in Women up to 55 Years of Age Vaccinated With Cervarix, the HPV-16/18 L1 AS04 Vaccine Candidate. Presented at: EURGIN; October 4-6, 2007; Monaco, France.
30. Markowitz LE, Dunne EF, Saraiya M, et al. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24.
31. Kane MA. Human papillomaviruses (HPV) vaccines: implementation and communication issues. J Fam Plann Reprod Health Care 2008;34:3-4.
32. 32. Ginsberg GM, Fisher M, Ben-Shahar I, et al. Cost utility analysis of vaccination against HPV in Israel. Vaccine 2007;25: 6677-6691. (Pubitemid 47337133)
33. FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers. Available at: http://www. fda.gov/bbs/topics/NEWS/ 2008/NEW01885.html.
34. Department of Health. HPV vaccine recommends for NHS immunization programme. 2007. Available at: http://nds.coi.gov.uk/environment/fullDetail.asp? ReleaseID=325799 &NewsAreaID=2.